Business Context and Reporting Period
This Form 6-K filing by Brookfield Renewable Partners L.P. covers the month of June 2016, with the report signed on June 6, 2016. The filing serves primarily to incorporate by reference various exhibits related to the company's Q1 2016 interim results and the acquisition of Isagen S.A.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the incorporated exhibits (specifically Exhibits 99.6, 99.7, and 99.8) rather than the cover document.
Material Changes and Acquisitions
- Isagen S.A. Acquisition: The filing incorporates a Business Acquisition Report dated April 11, 2016, along with separate audited financial statements for Isagen S.A. for the years ended December 31, 2013, 2014, and 2015.
- Pro Forma Data: Unaudited pro forma consolidated financial statements combining Brookfield Renewable Partners L.P. and Isagen S.A. for the year ended December 31, 2015, are included as Exhibit 99.5.
- Q1 2016 Results: The filing incorporates the Q1 2016 Interim Report, interim consolidated financial statements, and Management's Discussion and Analysis for the three months ended March 31, 2016.
Guidance, Outlook, and Risks
The filing text does not provide direct management commentary, guidance, or risk factors. These details are located in the incorporated Management's Discussion and Analysis (Exhibit 99.8) and the Interim Report (Exhibit 99.6). The filing notes that the information in Exhibits 99.1 to 99.10 is incorporated by reference into the registrant's registration statement on Form F-3 (File No. 333-197485).
Investor Verification Checklist
- Review Exhibit 99.7 for specific Q1 2016 revenue, earnings, and cash flow figures.
- Examine Exhibit 99.5 to understand the pro forma financial impact of the Isagen S.A. acquisition.
- Consult Exhibit 99.8 for management's discussion on liquidity, capital resources, and risks associated with the acquisition.
- Verify the details of the Isagen S.A. acquisition in Exhibit 99.3.